title: Low calcium dialysate and high-dose oral calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis patients.
abstract: We treated nineteen haemodialysis patients with secondary hyperparathyroidism with increasing oral doses of 1,25 dihydroxycholecalciferol (calcitriol) over a 12-week period and used low calcium dialysate (1.0 mmol/l) to prevent hypercalcaemia. Nine patients received daily calcitriol and ten received calcitriol thrice weekly, and at the end of the study the mean doses were 2.0 micrograms daily and 2.6 micrograms thrice weekly respectively. The regimen was well tolerated with nine episodes of mild hypercalcaemia, none of which were symptomatic. Mean PTH and alkaline phosphatase concentrations decreased from 62.0 pmol/l (15-125) to 22.0 pmol/l(1-70) (P less than 0.01), and 144 IU/l (48-461) to 123 IU/l (61-346) (P less than 0.05) respectively. Mean serum calcium increased from 2.33 mmol/l (2.05-2.55) to 2.52 mmol/l (2.26-2.67) (P less than 0.01). There were no significant changes in serum phosphate, magnesium, or aluminium concentrations and there were no significant differences in outcome between patients receiving daily therapy compared to those receiving it thrice weekly. A combination of high-dose oral calcitriol and low calcium dialysate can reverse secondary hyperparathyroidism without causing hypercalcaemia and these results suggest a benefit over conventional low-dose calcitriol.
authors: Renal Unit, Western Infirmary, Glasgow, Scotland, UK.
authors: W M
authors: WM
authors: Van der Merwe
authors: R S
authors: RS
authors: Rodger
authors: A C
authors: AC
authors: Grant
authors: F C
authors: FC
authors: Logue
authors: R A
authors: RA
authors: Cowan
authors: G H
authors: GH
authors: Beastall
authors: B J
authors: BJ
authors: Junor
authors: J D
authors: JD
authors: Briggs
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D002117:Calcitriol / Q000008:administration & dosage*; D002118:Calcium; D004334:Drug Administration Schedule; D005260:Female; D015312:Hemodialysis Solutions; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy / Q000628:therapy*; D007676:Kidney Failure, Chronic / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis
chemical_list: D015312:Hemodialysis Solutions; D002117:Calcitriol; D002118:Calcium